尿路感染症治療の世界市場レポート 2025年

尿路感染症治療の市場規模は、今後数年で安定した成長が見込まれます。2029年にはCAGR3.7％で124億5,000万米ドルに成長します。予測期間の成長は、非抗生物質治療の開発、耐性菌の増加、個別化治療アプローチ、電子医療や遠隔診察、公衆衛生意識向上プログラムなどに起因します。予測期間の主な動向には、マイクロバイオームベースの治療法、ファージ療法、ポイントオブケア検査、栄養介入、予防戦略の重視、地域ベースの介入などがあります。

尿路感染症の有病率の増加が、今後の尿路感染症治療市場の拡大を牽引するとみられます。尿路感染症は、腎臓、膀胱、尿管、尿道など泌尿器系のさまざまな部位に影響を及ぼす細菌感染症を包含します。尿路感染症の効果的な治療は、感染症に対処し治癒を促進する上で極めて重要です。2023年1月現在、米国国立衛生研究所（National Institute of Health）の報告によると、尿路感染症は米国で救急外来を受診する理由として7番目に多く、年間100万人以上が受診しています。これらの症例のうち22％（22万件）が複雑性尿路結石と考えられ、約10万件が入院に至っています。したがって、尿路感染症の有病率の増加は、尿路感染症治療市場の成長を促す重要な要因となっています。

高齢化は尿路感染症治療市場拡大の起爆剤になると予測されます。高齢化」とは、社会や人口における高齢者の割合が増加することを特徴とする人口動態の変化を指します。高齢者層では、免疫機能の低下や尿路構造の変化といった加齢に関連した要因によって尿路感染症（UTI）に対する感受性が高まるため、尿路感染症治療が必要となります。2022年10月現在、世界保健機関（WHO）は、60歳以上の世界人口が急速に増加しており、2050年までに2倍の21億人に達すると予測していることを強調しています。したがって、高齢化人口の増加が尿路感染症治療市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界尿路感染症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の尿路感染症治療市場：成長率分析
• 世界の尿路感染症治療市場の実績：規模と成長, 2019-2024
• 世界の尿路感染症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界尿路感染症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の尿路感染症治療市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ペニシリンとその組み合わせ
• キノロン
• セファロスポリン
• アミノグリコシド系抗生物質
• スルホンアミド
• アゾールとアムホテリシンB
• テトラサイクリン
• ニトロフラントイン
• 世界の尿路感染症治療市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 複雑な尿路感染症
• 合併症のないUT
• 世界の尿路感染症治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 婦人科・泌尿器科クリニック
• ドラッグストア
• 小売薬局
• オンラインドラッグストア
• 世界の尿路感染症治療市場ペニシリンとその組み合わせの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アモキシシリン
• アンピシリン
• アモキシシリンまたはクラブラン酸
• 世界の尿路感染症治療市場キノロンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シプロフロキサシン
• レボフロキサシン
• ノルフロキサシン
• 世界の尿路感染症治療市場セファロスポリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• セファレキシン
• セフトリアキソン
• セフォタキシム
• 世界の尿路感染症治療市場アミノグリコシド系抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ゲンタマイシン
• トブラマイシン
• アミカシン
• 世界の尿路感染症治療市場、スルホンアミドのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• スルファメトキサゾールまたはトリメトプリム
• スルファジアジン
• 世界の尿路感染症治療市場アゾールとアムホテリシンBのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• フルコナゾール
• イトラコナゾール
• アンホテリシンB
• 世界の尿路感染症治療市場、テトラサイクリンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ドキシサイクリン
• ミノサイクリン
• 世界の尿路感染症治療市場ニトロフラントインのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ニトロフラントイン一水和物
• ニトロフラントインマクロ結晶

第7章 地域別・国別分析

• 世界の尿路感染症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の尿路感染症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 尿路感染症治療市場：競合情勢
• 尿路感染症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Allergan Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Novartis International AG.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• GlaxoSmithKline PLC
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceutical Industries Ltd
• Dr. Reddy's Laboratories Ltd.
• Bio-Rad Laboratories Inc.
• Cipla Ltd
• Hikma Pharmaceuticals PLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 尿路感染症治療市場2029：新たな機会を提供する国
• 尿路感染症治療市場2029：新たな機会を提供するセグメント
• 尿路感染症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Urinary tract infection treatment involves medical procedures and methods aimed at eliminating bacterial infections affecting the urinary system, which can impact areas such as the bladder, urethra, ureters, kidneys, and other components of the urinary system.

The main types of drug classes in urinary tract infection treatment include penicillin and combinations, quinolones, cephalosporin, aminoglycoside antibiotics, Sulfonamides, azoles and amphotericin B, tetracycline, and nitrofurantoin. Penicillin, a beta-lactamase antibacterial medication, is utilized to manage a wide range of infections, including urinary tract infections (UTIs). It is effective against common bacteria causing UTIs and is generally well-tolerated. Indications for penicillin in urinary tract infection treatment include both complicated and uncomplicated UTIs. Distribution channels encompass hospital pharmacies, gynecology and urology clinics, drug stores, retail pharmacies, and online drug stores.

The urinary tract infection treatment market research report is one of a series of new reports from The Business Research Company that provides urinary tract infection treatment market statistics, including the urinary tract infection treatment industry global market size, regional shares, competitors with a urinary tract infection treatment market share, detailed urinary tract infection treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary tract infection treatment industry. This urinary tract infection treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urinary tract infection treatment market size has grown steadily in recent years. It will grow from $10.52 billion in 2024 to $10.78 billion in 2025 at a compound annual growth rate (CAGR) of 2.5%. The growth in the historic period can be attributed to antibiotic discoveries, urinary catheter use, clinical guidelines and protocols, patient awareness and education, women's health research

The urinary tract infection treatment market size is expected to see steady growth in the next few years. It will grow to $12.45 billion in 2029 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to development of non-antibiotic treatments, rise in resistant bacterial strains, personalized treatment approaches, elemedicine and remote consultations, public health awareness programs. Major trends in the forecast period include microbiome-based therapies, phage therapy, point-of-care testing, nutritional interventions, preventive strategies focus, community-based interventions.

The increasing prevalence of urinary tract infections is poised to drive the expansion of the market for urinary tract infection treatment in the future. Urinary tract infections encompass bacterial infections affecting various parts of the urinary system, including the kidneys, bladder, ureters, and urethra. Effective treatment of urinary tract infections is crucial in addressing the infection and fostering healing. As of January 2023, the National Institute of Health reported that urinary tract infections ranked as the seventh most common reason for emergency department visits in the USA, constituting over one million annual visits. Of these cases, 22% (220,000) were considered complicated UTIs, with around 100,000 resulting in hospital admissions. Consequently, the increasing prevalence of urinary tract infections is a significant driver of growth in the urinary tract infection treatment market.

The aging population is anticipated to be a catalyst for the expansion of the urinary tract infection treatment market. The term 'aging population' refers to a demographic shift characterized by a rising proportion of elderly individuals within a society or population. The elderly demographic requires urinary tract infection (UTI) treatment due to an elevated susceptibility to UTIs associated with age-related factors such as weakened immune function and alterations in urinary tract structure. As of October 2022, the World Health Organization highlighted that the global population of individuals aged 60 years and older is rapidly growing, projected to double by 2050, reaching 2.1 billion. Hence, the increasing aging population is propelling the growth of the urinary tract infection treatment market.

The adoption of advanced diagnostic technologies is an emerging trend gaining traction in the urinary tract infection treatment market. Companies in the market are focusing on innovative product development to maintain their competitive positions. In April 2023, AccessDx Laboratory, a US-based diagnostic laboratory, introduced the UTI PROx Panel. UTI PROx is designed to provide healthcare providers with enhanced insights to improve clinical care and decision-making when dealing with suspected, complex, and recurrent urinary tract infections.

Major companies operating in the urinary tract infection treatment market are concentrating on the development of innovative products such as Harncare bearberry tablets. These tablets serve as an herbal remedy for symptoms associated with lower urinary tract infections. Harncare Bearberry Tablets, formulated with the single crude drug bearberry, is the first tablet of its kind in Japan and is available as a second-class over-the-counter drug in pharmacies and drugstores across the country. In March 2022, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Harncare Bearberry tablets, addressing urinating discomfort and the sensation of residual urine.

In September 2022, GSK plc, a UK-based biopharmaceutical company, announced a licensing agreement with Spero Therapeutics, Inc. for tebipenem pivoxil hydrobromide (tebipenem HBr). This partnership aims to enable GSK to develop and commercialize tebipenem HBr, an innovative oral antibiotic designed to treat complicated urinary tract infections, thereby addressing a critical unmet medical need for effective alternatives to intravenous therapies. Spero Therapeutics, Inc. is a US-based biopharmaceutical company focused on treating urinary tract infections.

Major companies operating in the urinary tract infection treatment market include Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, AbbVie Inc., Allergan Plc, Bayer AG, Novartis International AG., Sanofi S.A., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca plc, GlaxoSmithKline PLC, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Cipla Ltd, Hikma Pharmaceuticals PLC, Lupin Limited, Almirall SA, Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Mylan N.V.

North America was the largest region in the urinary tract infection treatment market in 2024. The regions covered in the urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urinary tract infection treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urinary tract infection treatment market consists of sales of trimethoprim, sulfamethoxazole, cephalexin, and ceftriaxone. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urinary Tract Infection Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urinary tract infection treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urinary tract infection treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urinary tract infection treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Penicillin And Combinations; Quinolones; Cephalosporin; Aminoglycoside Antibiotics; Sulphonamides; Azoles And Amphotericin B; Tetracycline; Nitrofurantoin
• 2) By Indication: Complicated UTI; Uncomplicated UTI
• 3) By Distribution Channel: Hospital Pharmacies; Gynecology And Urology Clinics; Drug Stores; Retail Pharmacies; Online Drug Store
• Subsegments:
• 1) By Penicillin And Combinations: Amoxicillin; Ampicillin; Amoxicillin Or Clavulanate
• 2) By Quinolones: Ciprofloxacin; Levofloxacin; Norfloxacin
• 3) By Cephalosporin: Cephalexin; Ceftriaxone; Cefotaxime
• 4) By Aminoglycoside Antibiotics: Gentamicin; Tobramycin; Amikacin
• 5) By Sulphonamides: Sulfamethoxazole Or Trimethoprim; Sulfadiazine
• 6) By Azoles And Amphotericin B: Fluconazole; Itraconazole; Amphotericin B
• 7) By Tetracycline: Doxycycline; Minocycline
• 8) By Nitrofurantoin: Nitrofurantoin Monohydrate; Nitrofurantoin Macrocrystals
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; AbbVie Inc.; Allergan Plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urinary Tract Infection Treatment Market Characteristics

3. Urinary Tract Infection Treatment Market Trends And Strategies

4. Urinary Tract Infection Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Urinary Tract Infection Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Urinary Tract Infection Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Urinary Tract Infection Treatment Market Growth Rate Analysis
• 5.4. Global Urinary Tract Infection Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Urinary Tract Infection Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Urinary Tract Infection Treatment Total Addressable Market (TAM)

6. Urinary Tract Infection Treatment Market Segmentation

• 6.1. Global Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Penicillin And Combinations
• Quinolones
• Cephalosporin
• Aminoglycoside Antibiotics
• Sulphonamides
• Azoles And Amphotericin B
• Tetracycline
• Nitrofurantoin
• 6.2. Global Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Complicated UTI
• Uncomplicated UT
• 6.3. Global Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Gynecology And Urology Clinics
• Drug Stores
• Retail Pharmacies
• Online Drug Store
• 6.4. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Penicillin And Combinations, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amoxicillin
• Ampicillin
• Amoxicillin Or Clavulanate
• 6.5. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Quinolones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ciprofloxacin
• Levofloxacin
• Norfloxacin
• 6.6. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Cephalosporin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cephalexin
• Ceftriaxone
• Cefotaxime
• 6.7. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Aminoglycoside Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gentamicin
• Tobramycin
• Amikacin
• 6.8. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Sulphonamides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sulfamethoxazole Or Trimethoprim
• Sulfadiazine
• 6.9. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Azoles And Amphotericin B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fluconazole
• Itraconazole
• Amphotericin B
• 6.10. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Tetracycline, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Doxycycline
• Minocycline
• 6.11. Global Urinary Tract Infection Treatment Market, Sub-Segmentation Of Nitrofurantoin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nitrofurantoin Monohydrate
• Nitrofurantoin Macrocrystals

7. Urinary Tract Infection Treatment Market Regional And Country Analysis

• 7.1. Global Urinary Tract Infection Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Urinary Tract Infection Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Urinary Tract Infection Treatment Market

• 8.1. Asia-Pacific Urinary Tract Infection Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Urinary Tract Infection Treatment Market

• 9.1. China Urinary Tract Infection Treatment Market Overview
• 9.2. China Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Urinary Tract Infection Treatment Market

• 10.1. India Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Urinary Tract Infection Treatment Market

• 11.1. Japan Urinary Tract Infection Treatment Market Overview
• 11.2. Japan Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Urinary Tract Infection Treatment Market

• 12.1. Australia Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Urinary Tract Infection Treatment Market

• 13.1. Indonesia Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Urinary Tract Infection Treatment Market

• 14.1. South Korea Urinary Tract Infection Treatment Market Overview
• 14.2. South Korea Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Urinary Tract Infection Treatment Market

• 15.1. Western Europe Urinary Tract Infection Treatment Market Overview
• 15.2. Western Europe Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Urinary Tract Infection Treatment Market

• 16.1. UK Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Urinary Tract Infection Treatment Market

• 17.1. Germany Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Urinary Tract Infection Treatment Market

• 18.1. France Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Urinary Tract Infection Treatment Market

• 19.1. Italy Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Urinary Tract Infection Treatment Market

• 20.1. Spain Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Urinary Tract Infection Treatment Market

• 21.1. Eastern Europe Urinary Tract Infection Treatment Market Overview
• 21.2. Eastern Europe Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Urinary Tract Infection Treatment Market

• 22.1. Russia Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Urinary Tract Infection Treatment Market

• 23.1. North America Urinary Tract Infection Treatment Market Overview
• 23.2. North America Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Urinary Tract Infection Treatment Market

• 24.1. USA Urinary Tract Infection Treatment Market Overview
• 24.2. USA Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Urinary Tract Infection Treatment Market

• 25.1. Canada Urinary Tract Infection Treatment Market Overview
• 25.2. Canada Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Urinary Tract Infection Treatment Market

• 26.1. South America Urinary Tract Infection Treatment Market Overview
• 26.2. South America Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Urinary Tract Infection Treatment Market

• 27.1. Brazil Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Urinary Tract Infection Treatment Market

• 28.1. Middle East Urinary Tract Infection Treatment Market Overview
• 28.2. Middle East Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Urinary Tract Infection Treatment Market

• 29.1. Africa Urinary Tract Infection Treatment Market Overview
• 29.2. Africa Urinary Tract Infection Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Urinary Tract Infection Treatment Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Urinary Tract Infection Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Urinary Tract Infection Treatment Market Competitive Landscape And Company Profiles

• 30.1. Urinary Tract Infection Treatment Market Competitive Landscape
• 30.2. Urinary Tract Infection Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Allergan Plc Overview, Products and Services, Strategy and Financial Analysis

31. Urinary Tract Infection Treatment Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Novartis International AG.
• 31.3. Sanofi S.A.
• 31.4. Bristol-Myers Squibb Company
• 31.5. Thermo Fisher Scientific Inc.
• 31.6. AstraZeneca plc
• 31.7. GlaxoSmithKline PLC
• 31.8. Eli Lilly and Company
• 31.9. Boehringer Ingelheim GmbH
• 31.10. Teva Pharmaceutical Industries Ltd
• 31.11. Sun Pharmaceutical Industries Ltd
• 31.12. Dr. Reddy's Laboratories Ltd.
• 31.13. Bio-Rad Laboratories Inc.
• 31.14. Cipla Ltd
• 31.15. Hikma Pharmaceuticals PLC

32. Global Urinary Tract Infection Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Urinary Tract Infection Treatment Market

34. Recent Developments In The Urinary Tract Infection Treatment Market

35. Urinary Tract Infection Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Urinary Tract Infection Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Urinary Tract Infection Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Urinary Tract Infection Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer